VANCOUVER--(BUSINESS WIRE)--ProtoKinetix Inc. (OTCBB:PKTX) is pleased to announce that the TF Chem scientific team, on the behalf of ProtoKinetix, has synthesized a new AAGP™ derivative. TF Chem, headed up by ProtoKinetix’ Chief Scientist Dr. Geraldine Deliencourt, has successfully developed a prototype derivative of AAGP™. It is confidently expected that this prototype derivative will significantly enhance the already powerful preservative characteristics of AAGP™. Advanced Nuclear Magnetic Resonance (NMR) analysis has confirmed the successful structure of this prototype molecule. Dr. Deliencourt says, “This new structure has the potential to increase AAGP™ bioactivity by a factor of over one hundred times.”
